GlaxoSmithKline to lay off more than 240 workers in US, UK

GlaxoSmithKline will cut 240 to 250 jobs at sites in Pennsylvania and the United Kingdom, according to EndPoints News.

The layoffs come as the drugmaker works to revise its research and development strategy under its new R&D chief Hal Barron.

Most of the job cuts will affect chemists at its facility in Upper Providence, Pa., as well as some administrative roles.

A few R&D jobs at its facility in Stevenage, U.K., also will be eliminated.

Read the full report here.


More articles on pharmacy:
PBM hearing should prompt bill to ban 'secrecy' in drug industry, senator says
Republicans tell drugmakers that complying with House probe could hurt their stock prices
Hawaii primary care network opens in-house pharmacy

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.